Selecting targets for cancer prevention: where do we go from here?

Area of Science:

• Oncology
• Cancer Prevention
• Drug Development

Background:

• Metastatic epithelial cancers remain largely incurable, driving interest in prevention strategies.
• Despite some successes, cancer prevention trials have yielded limited changes in medical practice and occasional harm.
• Recent serious adverse events highlight the need for improved approaches in clinical chemoprevention.

Purpose of the Study:

• To re-evaluate the approach to clinical chemopreventive drug development.
• To establish a framework for selecting agents in future cancer prevention trials.

Main Methods:

• Review of recent clinical chemoprevention trials and their outcomes.
• Analysis of serious side effects reported in cancer prevention studies.
• Development of a proposed framework for agent selection.

Main Results:

• Few cancer prevention strategies have translated into widespread medical practice.
• Significant side effects have been observed in some chemoprevention trials.
• A need exists for a structured approach to agent selection in future trials.

Conclusions:

• Current strategies for clinical chemopreventive drug development require re-evaluation.
• A robust framework for agent selection is essential for advancing cancer prevention research.
• Improved methodologies are needed to ensure the safety and efficacy of cancer prevention interventions.